ABPO Abpro Holdings Inc.
Listings ·
Nasdaq filed a Form 25 notice dated 2026-09-30 to strike Abpro Holdings' Class A Common Stock and warrants from listing. The company had already received a delisting notice effective February 23, 2026, and its shares trade on the OTC Pink Limited Market.
Abpro Holdings said Miles Suk resigned as chairman of its board effective August 25, 2026. The board will appoint a successor chair at its next regularly scheduled meeting.
Abpro Holdings said Nasdaq's Listing and Hearing Review Council reaffirmed the panel's decision to delist its common stock and public warrants.
Nasdaq told Abpro on September 30, 2025 that it had not regained compliance with the $1.00 minimum bid price. The company says it will ask an appeal panel for a hearing, which would stay the suspension, but the filing gives no assurance the panel will grant it more time.
The company found it had understated liabilities under one of its license agreements and expects a $3.3 million increase in each affected period. Statements for three earlier periods should no longer be relied upon.
The company says it needs more time to prepare its financial statements and expects to file within the fifteen-day extension period.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $183,000 | |
| Research and development | $989,000 | $3.0 million |
| Cash from operations | -$6.0 million | -$9.0 million |
| Cash and equivalents | $82,000 | $2.9 million |
Our latest story on this, dated Sep 30, 2026: "Nasdaq files to remove Abpro Holdings stock and warrants from listing". The story links the filing or release it is based on. Read the story.
Abpro Holdings Inc. trades under the ticker ABPO on OTC.
Abpro Holdings Inc. is listed on OTC.
The SEC Central Index Key (CIK) for Abpro Holdings Inc. is 1893219. Its filings are on SEC EDGAR.
5,896,048 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Abpro Holdings Inc. under United States.
Our directory classifies Abpro Holdings Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Abpro Holdings Inc. is US0008472021.
aibio.space lists Abpro Holdings Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$989,000 in the fiscal year ended Dec 31, 2025, per its annual report.
$4.2 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Abpro Holdings, dated Sep 30, 2026: "Nasdaq files to remove Abpro Holdings stock and warrants from listing". Nasdaq filed a Form 25 notice dated 2026-09-30 to strike Abpro Holdings' Class A Common Stock and warrants from listing. The company had already received a delisting notice effective February 23, 2026, and its shares trade on the OTC Pink Limited Market. Source.
From our story of Apr 15, 2025: The same report says management has concluded that uncertainties around its ability to raise additional capital raise substantial doubt about its ability to continue as a going concern. Source.
Our latest distress story, dated Apr 15, 2025: "Abpro Holdings restates prior statements over understated license liabilities". The company found it had understated liabilities under one of its license agreements and expects a $3.3 million increase in each affected period. Statements for three earlier periods should no longer be relied upon. Source.
Filed to remove its shares from exchange listing. SEC Form 25-NSE. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 7.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 4.02). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). Source
Reported a merger or acquisition agreement. SEC Form 425. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio